Lucid Diagnostics Inc. (LUCD), a cancer prevention diagnostics company and subsidiary of PAVmed Inc., Tuesday has entered into subscription agreements with accredited investors to sell 13,939,331 shares of common stock at $1.1 per share in a registered direct offering. The company expects to raise approximately $15.3 million in gross proceeds, with around $0.8 million allocated for placement agent fees and other expenses.
Canaccord Genuity is serving as the sole placement agent, and the offering is anticipated to close on March 5, 2025. The net proceeds will be used for working capital and general corporate purposes.
The offering is being conducted under a Form S-3 registration statement (File No. 333-268560), declared effective by the SEC on December 6, 2022. A prospectus supplement will be filed with the SEC, and electronic copies will be available on the SEC's website or through Canaccord Genuity.
This announcement does not constitute an offer or solicitation to buy or sell these securities in any jurisdiction where such actions would be unlawful.
LUCD is currently trading at $1.2795 or 4.5149% lower on the Nasdaq Capital Market.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.